Novo Nordisk, the maker of Wegovy, announced exclusively on "Good Morning America" Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

The pharmaceutical company announced it would be partnering with Hims & Hers., LifeMD and Ro. to provide all five dose strengths of its weight-loss GLP-1 medication Wegovy at a reduced cost of $499.

As part of its deal with Novo, Hims, along with LifeMD Inc., and Ro will sell a month’s supply of Wegovy starting at $499, a 63 percent discount, before subscription fees. Lilly also announced ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound Hims & Hers and Novo also said the two companies are collaborating beyond the Wegovy partnership but didn't ...

directly through the telehealth platforms of Hims & Hers along with telehealth competitors LifeMD and Ro. Hims & Hers, LifeMD stocks skyrocket after inking deal with Novo Nordisk to sell Wegovy ...

70. Novo Nordisk is expanding its efforts to sell its obesity drug Wegovy directly to patients, striking agreements with telehealth companies including Hims & Hers, Ro, and LifeMD. Novo last month ...

Hims & Hers Health announced on Tuesday it will ... Two other telehealth companies, Ro and Life MD, similarly unveiled partnerships with Novo Nordisk on Tuesday that will involve integrating ...

particularly those without insurance coverage," Ro CEO Zach Reitano said in a release. Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug ...